New data from the Personalised Disease Monitoring in Metastatic Breast Cancer study! 🎉 At #SABCS24! Come and listen to Dr. Sascha Howell present the latest findings with our biomarker DiviTum TKa. Poster session P5-02-16. Grab the chance to pose questions on Dec 13th, at 12:30-2 PM CT! See our SIX other poster presentations: https://loom.ly/I3O7VNA #biomarker #breastcancer #personalizedmedicine #divitum
Biovica International AB’s Post
More Relevant Posts
-
[ON-DEMAND WEBINAR] Learn how to leverage microplate reader technology to streamline and enhance your organoid-based cancer research. This NEW webinar, presented by Krystal Courtney Belmonte, Ph.D. and Angeline Lim, Ph.D. showcases innovative techniques for identifying and assessing drug candidates using patient-derived colorectal #cancer #organoids. https://lnkd.in/e9p2Rayd
-
Pharmacologist/Drug Discoverer/Community Builder/NAIAD/#thebutterflyeffect #disruptiveinnovator
Please join CellCarta and RareCyte, Inc. for this insightful webinar on Her2 expression, next week (May 29th). #PrecisionMedicine #CirculatingTumorCells #LiquidBiopsy #CellCarta #RareCyte
Upcoming Webinar: Detecting HER2 Expression from a Single Tube of Blood Join us and CellCarta to discover a novel method for oncosome detection. Dr. Eszter Papp will present findings from a proof-of-concept study integrating oncosomes, CTCs, and cfDNA data to identify metastatic breast cancer patients with elevated HER2 expression. Register here, https://lnkd.in/gi833GjU #PrecisionMedicine #CirculatingTumorCells #LiquidBiopsy #RareCyte
-
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
SALES EXECUTIVE - BUSINESS DEVELOPMENT - RELATIONSHIP MANAGEMENT - OPERATIONS LEADERSHIP - ELEVATING BUSINESS PERFORMANCE - EXPEDITING GROWTH AND PROFITABILITY
Homologous recombination deficiency (HRD) testing helps guide personalized PARP inhibitor therapy for patients living with ovarian cancer. Tune in to Labcorp Perspectives to hear from Dr. Rebecca Previs and Dr. Alison Roos on how expanded HRD testing can transform precision medicine and improve outcomes for ovarian cancer patients. Check out the latest episode to learn more about the future of precision medicine: #PrecisionOncology#PersonalizedMedicine #CancerResearch #GynOnc
-
Sales & Marketing Director, Combat Medical | Developing world leading hyperthermic technologies to optimise the treatment of bladder, colon and ovarian cancer.
Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer. 7. TAR-200 Early promising results from the SunRISE-1 phase 2b trial in BCG-unresponsive CIS were presented at the 2023 American Urological Association. TAR-200 is a novel drug delivery system for the sustained local release of gemcitabine in the bladder was associated with an overall complete response rate of 73%. Tomorrow: HIVEC-HEAT #medicalinnovation #bladdercancer #HIVEC #CombatMedical
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
🎗️ This Pancreatic Cancer Awareness Month, we're spotlighting key research: Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia (IPMN): Findings from the multicentre ADENO-IPMN study 📖 Read the full study here: https://buff.ly/4eC2I8l #PancreaticCancerAwareness #CancerResearch #PancreaticCancer #IPMN
-
-
Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer. 7. TAR-200 Early promising results from the SunRISE-1 phase 2b trial in BCG-unresponsive CIS were presented at the 2023 American Urological Association. TAR-200 is a novel drug delivery system for the sustained local release of gemcitabine in the bladder was associated with an overall complete response rate of 73%. Tomorrow: HIVEC-HEAT #medicalinnovation #bladdercancer #HIVEC #CombatMedical
